MNKYPOX Monkeypox - Consolidated Thread.

psychgirl

psychgirl

Has No Life - Lives on TB
bw

bw

Fringe Ranger
psychgirl said:
A parent asking about spreading monkeypox in college

In your opinion how many people can one infected person spread it in a college or school?
Click to expand...

The average student is less promiscuous than their reputation, but a super-spreader (so to speak) might be impressive.

Colleges and daycare centers are going to be interesting.
 
bw

bw

Fringe Ranger
Headed toward the half million neighborhood at end September. These are the registered cases, of course. Estimates are the unregistered might be 10x. Schools are a total unknown at this point. Not a good picture.
 
psychgirl

psychgirl

Has No Life - Lives on TB
bw said:
If they stretch the vax, the maker is going to forego a lot of profit. I understand their concern.
Click to expand...
They’re worried it won’t work properly. That’s what I got out of this.
But ohh yes, you can BET, losing $$$$ is their concern, too!
 
somewherepress

somewherepress

Has No Life - Lives on TB
childrenshealthdefense.org

Without Clinical Trials, FDA Authorizes Modified Monkeypox Vaccine, Expands Eligibility to ‘High-Risk’ Children

Bypassing normal clinical trial guidance, the U.S. Food and Drug Administration on Tuesday expanded the Emergency Use Authorization for the Jynneos monkeypox vaccine to allow for an alternative method of injection and for “high-risk” children under 18 to get the vaccine.
childrenshealthdefense.org childrenshealthdefense.org

Without Clinical Trials, FDA Authorizes Modified Monkeypox Vaccine, Expands Eligibility to ‘High-Risk’ Children

Bypassing normal clinical trial guidance, the U.S. Food and Drug Administration on Tuesday expanded the Emergency Use Authorization for the Jynneos monkeypox vaccine to allow for an alternative method of injection and for “high-risk” children under 18 to get the vaccine.
By
Megan Redshaw
41






Link copied

Miss a day, miss a lot. Subscribe to The Defender's Top News of the Day. It's free.
The U.S. Food and Drug Administration (FDA) on Tuesday expanded the Emergency Use Authorization (EUA) for the Jynneos monkeypox vaccine to allow for an alternative method of injection the agency said would help conserve low supplies.
The expanded EUA also allows the vaccine to be used in children under age 18 who are at “high risk” of infection.
Prior to issuing the expanded EUA, the FDA confirmed that “numerous” children were granted access to the vaccine on a “case-by-case basis” through a special permission process — even though the vaccine was not approved or authorized for emergency use in that age group — ABC News reported on Aug. 4.

News of the potential dose-sparing recommendations prompted some congressional staff — including from the Centers for Disease Control and Prevention (CDC) and U.S. Department of Health and Human Services — to question federal health officials about whether using the alternative injection method could affect the efficacy of the shot.

“They seemed to have no good answers for us, other than denying that it would impact things,” an individual who attended a briefing on the matter told Politico. “But they didn’t present any data.”

According to CNBC, monkeypox is rarely fatal and no deaths have been reported in the U.S. However, some patients need to be hospitalized to manage lesions, which can be painful.

Under the expanded EUA, healthcare providers can administer Bavarian Nordic’s Jynneos vaccine through intradermal injection — meaning between layers of the skin rather than below the skin — instead of subcutaneously, or beneath the skin.

The change in injection method will increase available doses fivefold — from 441,000 to more than 2.2 million — as intradermal injection uses only a fraction of the dose but provides the same protection, health officials said at a White House briefing.

Download for Free: Robert F. Kennedy's New Book — ‘A Letter to Liberals’
"}" data-sheets-userformat="{"2":6659,"3":{"1":0},"4":{"1":2,"2":65280},"12":0,"14":{"1":2,"2":2236962},"15":"Arial, Helvetica, sans-serif"}" style="margin: 0px; padding: 0px; border: 0px; outline: 0px; vertical-align: baseline;">


Download for Free: Robert F. Kennedy's New Book — ‘A Letter to Liberals’


The FDA said it determined the “known and potential benefits” of the monkeypox vaccine “outweigh the known and potential risks for the authorized uses.”


FDA Commissioner Dr. Robert Califf said in a press release:

“In recent weeks the monkeypox virus has continued to spread at a rate that has made it clear our current vaccine supply will not meet the current demand. The FDA quickly explored other scientifically appropriate options to facilitate access to the vaccine for all impacted individuals.

“By increasing the number of available doses, more individuals who want to be vaccinated against monkeypox will now have the opportunity to do so.”

Jynneos was approved in 2019 for the prevention of smallpox and monkeypox in high-risk adults 18 and older. The approval specified that the vaccine was to be administered subcutaneously, in two doses 28 days apart.

Using the intradermal method, the vaccine still will need to be administered in two doses, four weeks apart, the FDA said.

Children under 18 who are at high risk of monkeypox infection can receive the vaccine by subcutaneous injection, as it is easier to administer and there is not as much data available on the use of the vaccine in this age group.

The move to allow monkeypox vaccination in children under 18 is based on findings from the vaccine’s use in adults and on data on pediatric smallpox vaccination, CNN reported.

According to the CDC, Jynneos is approved to be administered subcutaneously into the fatty tissue over the triceps area in the upper arm.

The vaccine is administered as a “live Vaccinia virus preparation that is inoculated into the skin by pricking the skin surface.”

Although the National Institute of Allergy and Infectious Diseases is conducting a dose-sparing study of the Jynneos vaccine using intradermal injection, it could take months to complete, Politico reported.

In the meantime, the FDA based its authorization to allow the vaccine to be administered intradermally on data from a 2015 study of Jynneos in 524 participants, which “found a similar immune response when the vaccine was given intradermally in doses one-fifth the size of those given subcutaneously.”

Only the abstract is publicly accessible, and it is unclear from the abstract whether researchers assessed a smallpox antigen from the variola virus or an antigen from a monkeypox virus.

As The Defender reported, even the FDA acknowledged neutralizing antibodies do not correlate with protection, nor does protection against one pathogen necessarily correlate to protection against another.

“There is no traditional assessment of this vaccine … because there weren’t smallpox cases, and the monkeypox outbreaks before this were not large enough to really do a clinical trial,” Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said Tuesday.

“We want to collect outcome data, as we do with all vaccines,” Marks said. “And I’d also point out that the NIH [National Institutes of Health] will be mounting a clinical trial and is working through the logistics of that now.”

CDC guidance ‘discourages variations from the recommended route, site, volume, or number of doses of any vaccine’

On a call with reporters, Califf said the “overall safety and efficacy profile [of Jynneos] will not be sacrificed” with a dose-sparing approach, which Dr. Anthony Fauci, chief medical advisor to President Biden, touted as a ”promising solution to the vaccine shortage.”

According to the CDC’s Advisory Committee on Immunization Practices, best practice guidance for the administration of a vaccine is normally “derived from data from clinical trials, practical experience, normal intervals of health care visits and theoretical considerations.”

The committee “discourages variations from the recommended route, site, volume, or number of doses of any vaccine” as “variation from the recommended route and site can result in inadequate protection.”

The CDC website lists numerous examples where the method of administering a vaccine alters immunogenicity — the ability of a foreign substance, such as an antigen, to provoke an immune response in the human body.

A paper published in 2015, in the Expert Review of Vaccines assessed the effect of vaccine administration modality on immunogenicity and efficacy.

The authors found the “route of delivery can affect the vaccine localization that may influence the priming of immune cells as well as consequential local and systemic immune responses.”

They went on to say that “the choice of one strategy over the other depends on the type of vaccine and protective immunity needed to conquer the disease based on the route of infection and transmission.”

The FDA’s decision to authorize a new route of administration for Jynneos comes less than a week after the Biden administration declared monkeypox a public health emergency, allowing government health agencies to authorize unapproved medical products or uses of approved medical products to fight the spread of the virus.
 
Cascadians

Cascadians

Leska Emerald Adams
Read this. It should scare the shit out of you. Scientific confirmation of human to dog monkeypox. Prepare yourself mentally so you can resist and survive.

They are going to come after us. They are going to try to force kill our dogs and cats. RESIST! Heap love on your fur companions. Do not let anybody harm them for any reason! Do not give in to fear. This disease is survivable. Use anti-virals to conquer it.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01487-8/fulltext

Evidence of human-to-dog transmission of monkeypox virus

"Human monkeypox virus is spreading in Europe and the USA among individuals who have not travelled to endemic areas.
1On July 23, 2022, monkeypox was declared a Public Health Emergency of International Concern by WHO Director-General Tedros Adhanom Ghebreyesus.
2Human-to-human transmission of monkeypox virus usually occurs through close contact with the lesions, body fluids, and respiratory droplets of infected people or animals.
3The possibility of sexual transmission is being investigated, as the current outbreak appears to be concentrated in men who have sex with men and has been associated with unexpected anal and genital lesions.
1,
4 Whether domesticated cats and dogs could be a vector for monkeypox virus is unknown. Here we describe the first case of a dog with confirmed monkeypox virus infection that might have been acquired through human transmission.
Two men who have sex with men attended Pitié-Salpêtrière Hospital, Paris, France, on June 10, 2022 (appendix). One man (referred to as patient 1 going forward) is Latino, aged 44 years, and lives with HIV with undetectable viral loads on antiretrovirals; the second man (patient 2) is White, aged 27 years, and HIV-negative. The men are non-exclusive partners living in the same household. They each signed a consent form for the use of their clinical and biological data, and for the publication of anonymised photographs. The men had presented with anal ulceration 6 days after sex with other partners. In patient 1, anal ulceration was followed by a vesiculopustular rash on the face, ears, and legs; in patient 2, on the legs and back. In both cases, rash was associated with asthenia, headaches, and fever 4 days later (figure A, B).

Monkeypox virus was assayed by real-time PCR (LightCycler 480 System; Roche Diagnostics, Meylan, France). In patient 1, virus was detected in skin and oropharynx samples; whereas in patient 2, virus was detected in anal and oropharynx samples.
12 days after symptom onset, their male Italian greyhound, aged 4 years and with no previous medical disorders, presented with mucocutaneous lesions, including abdomen pustules and a thin anal ulceration (figure C, D; appendix). The dog tested positive for monkeypox virus by use of a PCR protocol adapted from Li and colleagues
5 that involved scraping skin lesions and swabbing the anus and oral cavity. Monkeypox virus DNA sequences from the dog and patient 1 were compared by next-generation sequencing (MinION; Oxford Nanopore Technologies, Oxford, UK). Both samples contained virus of the hMPXV-1 clade, lineage B.1, which has been spreading in non-endemic countries since April, 2022, and, as of Aug 4, 2022, has infected more than 1700 people in France, mostly concentrated in Paris, where the dog first developed symptoms. Moreover, the virus that infected patient 1 and the virus that infected the dog showed 100% sequence homology on the 19·5 kilobase pairs sequenced.
The men reported co-sleeping with their dog. They had been careful to prevent their dog from contact with other pets or humans from the onset of their own symptoms (ie, 13 days before the dog started to present cutaneous manifestations).
In endemic countries, only wild animals (rodents and primates) have been found to carry monkeypox virus.
6However, transmission of monkeypox virus in prairie dogs has been described in the USA
7and in captive primates in Europe
8 that were in contact with imported infected animals. Infection among domesticated animals, such as dogs and cats, has never been reported.
To the best of our knowledge, the kinetics of symptom onset in both patients and, subsequently, in their dog suggest human-to-dog transmission of monkeypox virus. Given the dog's skin and mucosal lesions as well as the positive monkeypox virus PCR results from anal and oral swabs, we hypothesise a real canine disease, not a simple carriage of the virus by close contact with humans or airborne transmission (or both). Our findings should prompt debate on the need to isolate pets from monkeypox virus-positive individuals. We call for further investigation on secondary transmissions via pets."
 
bw

bw

Fringe Ranger
oops said:
So they are once again stampedin ppl into usin an tested vax...while the illness is spreadin... what could possibly go wrong again...sigh
Click to expand...

The vax is tested, but they're using an untested injection method. It's curious. Perhaps it's all part of ratcheting up fear, but I'd expect more mainstream stories if that's the goal. This whole pandemic is going to be about fear, pain, scarring, and not much about mortality. (Though WuFlu wasn't all that dangerous except to the elderly.)
 
You must log in or register to reply here.
Top